Immunic, Inc. Common Stock (IMUX) Stock
Fundamentals
Recent news

Immunic to host virtual relapsing MS R&D Day on September 9
Immunic to host virtual relapsing MS R&D Day on September 9
IMUX

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
IMUX

Immunic advances MS drug toward key Phase 3 data, expects results by year-end
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
IMUX

Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
IMUX
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Immunic to host virtual relapsing MS R&D Day on September 9
Immunic to host virtual relapsing MS R&D Day on September 9
IMUX

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
IMUX

Immunic advances MS drug toward key Phase 3 data, expects results by year-end
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
IMUX

Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
IMUX

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
IMUX

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
IMUX

Immunic advances Phase 3 MS program, eyes topline data by year-end
Immunic advances Phase 3 MS program, eyes topline data by year-end
IMUX

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout
Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout
IMUX

Immunic to implement 1-for-10 reverse stock split
Immunic to implement 1-for-10 reverse stock split
IMUX

Immunic appoints biopharmaceutical executive Jon Congleton to board
Immunic appoints biopharmaceutical executive Jon Congleton to board
IMUX
About Immunic, Inc. Common Stock
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jason Tardio M.B.A. | COO & President | 1977 |
| Mr. Glenn Whaley CPA | Chief Financial Officer | 1968 |
| Mr. Erik Lundgren | CEO & Director | 1978 |
| Dr. Hella Kohlhof | Co-Founder & Chief Scientific Officer | 1973 |
| Ms. Jessica Breu | Vice President of Investor Relations & Communications | — |
| Mr. Inderpal Singh | General Counsel | 1966 |
| Mr. Patrick Walsh | Chief Business Officer | 1983 |
| Mr. Werner Gladdines | Chief Development Officer | 1979 |
| Dr. Michael A. Panzara M.D., M.P.H. | Chief Medical Officer | 1967 |
| Mr. Chitrang Davé | Chief Data & Digital Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
2 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +6.8 | +55.0 | +1.6 | -5.7 | +12.1 | -35.9 |
Corporate actions
Upcoming
No upcoming corporate actions for IMUX



